Form 4: Clover Health Director Acquires 60,975 Shares Through Restricted Stock Units

Demetrios L. Kouzoukas, a director at Clover Health Investments, Corp., acquired 60,975 shares of Class A Common Stock through a grant of restricted stock units.

Summary

• Demetrios L. Kouzoukas, a director of Clover Health Investments, Corp., received 60,975 shares of Class A Common Stock.
• These shares were granted as restricted stock units (RSUs).
• The RSUs will vest fully on January 6, 2026, one year after the grant date.
• Vesting is contingent upon Mr. Kouzoukas' continued service as a director until the vesting date.
• Following this transaction, Mr. Kouzoukas directly owns 526,615 shares of Class A Common Stock.

Sentiment

Score: 7

Explanation: The document reflects a standard transaction of equity compensation for a director, which is generally viewed positively as it aligns interests. There are no negative implications.

Positives

• The grant of RSUs to a director aligns their interests with the long-term success of the company.
• The vesting period encourages continued service and commitment from the director.

Risks

• The vesting of the RSUs is contingent on the director's continued service, which could be a risk if the director were to leave the company before the vesting date.

Future Outlook

The restricted stock units will vest on January 6, 2026, contingent on the director's continued service.

Industry Context

This type of equity grant is a common practice for aligning the interests of directors with the long-term performance of the company. It is a standard form of compensation in the corporate world.

Comparison to Industry Standards

• Equity grants, such as restricted stock units, are a common form of compensation for directors across various industries.
• Companies like UnitedHealth Group (UNH) and Humana (HUM) also use similar equity-based compensation for their board members.
• The vesting period of one year is fairly standard for these types of grants, ensuring continued service and commitment from the director.

Stakeholder Impact

• Shareholders may view this positively as it aligns the director's interests with the company's long-term performance.
• The grant of RSUs does not have a direct impact on employees, customers, suppliers, or creditors.

Next Steps

• The director will continue to serve on the board.
• The restricted stock units will vest on January 6, 2026, if the director remains in service.

Key Dates

Keywords

restricted stock units, RSUs, director, share acquisition, Class A Common Stock, Clover Health, CLOV, insider trading